Ignite Creation Date:
2025-12-24 @ 11:59 AM
Ignite Modification Date:
2026-01-01 @ 1:16 PM
Study NCT ID:
NCT01250561
Status:
COMPLETED
Last Update Posted:
2010-12-01
First Post:
2010-11-29
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Reduction of Postherpetic Neuralgia in Herpes Zoster
Sponsor:
Center for Clinical Studies, Texas
Organization:
Study Overview
Official Title:
None
Status:
COMPLETED
Status Verified Date:
2010-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The addition of gabapentin therapy to standard antiviral treatment with valacyclovir in acute herpes zoster patients will decrease the incidence of post-herpetic neuralgia.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: